Harrow, Inc. (HROW): Long-Term Debt
$250.00M
As of 2025-12-31
+18.1%
3-year compound annual growth
+65.7%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $250.00M | -4.8% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $262.74M | +6.5% | 2025-03-27, Balance as of period end |
| 2023-12-31 | $246.72M | +62.6% | 2024-03-19, Balance as of period end |
| 2022-12-31 | $151.77M | +47.3% | 2023-03-23, Balance as of period end |
| 2021-12-31 | $103.03M | +415.0% | 2022-03-10, Balance as of period end |
| 2020-12-31 | $20.00M | n/a | 2021-03-08, Balance as of period end |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $23.46M | 0.0% | 2019-03-12, Balance as of period end |
| 2017-12-31 | $23.46M | n/a | 2018-03-08, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $22.68M | -66.7% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
Compare HROW, ARVN, XERS, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗